This article summarized the latest R&D progress of Sulfanilamide, the Mechanism of Action for Sulfanilamide, and the drug target R&D trends for Sulfanilamide.
The study on Atrial Fibrillation using Abelacimab was prematurely ended by the Data Monitoring Committee due to a massive decrease in bleeding compared to a DOAC.
This article summarized the latest R&D progress of Sulfadiazine, the Mechanism of Action for Sulfadiazine, and the drug target R&D trends for Sulfadiazine.
Interleukin-1 receptor-associated kinases (IRAKs) were initially identified as serine/threonine kinases that can bind to the interleukin-1 receptor (IL-1R) upon induction by the pro-inflammatory cytokine interleukin-1 (IL-1).
This article summarized the latest R&D progress of Cefpodoxime proxetil, the Mechanism of Action for Cefpodoxime proxetil, and the drug target R&D trends for Cefpodoxime proxetil.
This article summarized the latest R&D progress of Sulfacetamide sodium, the Mechanism of Action for Sulfacetamide sodium, and the drug target R&D trends for Sulfacetamide sodium.
This article summarized the latest R&D progress of Sodium zirconium cyclosilicate, the Mechanism of Action for Sodium zirconium cyclosilicate, and the drug target R&D trends for Sodium zirconium cyclosilicate.